CFRD progresses through two clinical phases; in early disease, postprandial hyperglycemia predominates and can be detected by continuous glucose monitoring (CGM) or 2‐h OGTT with 30‐min sampling, revealing transient postprandial glucose fluctuations indicative of an impaired first‐phase insulin response. The gene discussed is INS; the disease is cystic fibrosis-related diabetes.